Purpose of Review

In this review, we discuss the evidence supporting the effects of statins on mast cells (MCs) in atherosclerosis and their molecular mechanism of action.

Recent Findings

Statins or HMG-CoA reductase inhibitors are known for their lipid-lowering properties and are widely used in the prevention and treatment of cardiovascular diseases. There is growing evidence that statins have an inhibitory effect on MCs, which contributes to the pleiotropic effect of statins in various diseases. MCs are one of the crucial effectors of the immune system which play an essential role in the pathogenesis of multiple disorders. Recent studies have shown that MCs are involved in the development of atherosclerotic plaques. MCs secrete various inflammatory cytokines (IL-6, IL4, TNF-α, and IFNγ) and inflammatory mediators (histamine, tryptase, proteoglycans) after activation by various stimulants. This, in turn, will exacerbate atherosclerosis. Statins suppress the activation of MCs via IgE inhibition which leads to inhibition of inflammatory mediators and cytokines which are involved in the development and progression of atherosclerosis.

Summary

In keeping with this evidence presented here, MCs can be considered as one of the therapeutic targets for statins in the treatment of atherosclerosis.

中文翻译：

---

他汀类药物通过肥大细胞在动脉粥样硬化的病理生理中的作用。

审查目的

在这篇综述中，我们讨论了支持他汀类药物对动脉粥样硬化中肥大细胞（MC）的作用及其分子作用机制的证据。

最近的发现

他汀类或HMG-CoA还原酶抑制剂以其降脂特性而闻名，并广泛用于预防和治疗心血管疾病。越来越多的证据表明他汀类药物对MC具有抑制作用，这有助于他汀类药物在多种疾病中的多效性。MC是免疫系统的关键效应物之一，其在多种疾病的发病机理中起着至关重要的作用。最近的研究表明，MC参与动脉粥样硬化斑块的形成。在通过各种刺激物激活后，MC分泌出各种炎性细胞因子（IL-6，IL4，TNF-α和IFNγ）和炎性介质（组胺，类胰蛋白酶，蛋白聚糖）。反过来，这会加剧动脉粥样硬化。

概要

根据此处提供的证据，MC可被认为是他汀类药物在动脉粥样硬化治疗中的治疗目标之一。